EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mollugin as a Plant‐Derived Bioactive: Preclinical Pharmacology, Structure–Activity Relationships, Pharmacokinetic Evidence and Safety Requirements for Food–Health Translation

Mert İlhan, Hasya Nazlı Gök, İpek Süntar, William N. Setzer, Javad Sharifi‐Rad, Daniela Calina

Food Safety and Health · 20.11.2026

DOI: 10.1002/fsh3.70132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Food Safety and Health, online erschienen am 20.11.2026. Verfasst von Mert İlhan und 5 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mollugin is a naturally occurring naphthopyran compound isolated from Rubia cordifolia L. and other medicinal plants. Its diverse biological activities have attracted research interest, particularly in cancer‐related experimental models. This narrative review critically examines the phytochemistry, structure–activity relationships, preclinical pharmacology, pharmacokinetics, and toxicological evidence of mollugin, with emphasis on its potential relevance to food–health applications. Available pharmacological evidence is predominantly derived from in vitro studies and a limited number of animal models. Experimental findings indicate that mollugin modulates apoptosis, autophagy, ferroptosis, and signaling pathways associated with cell proliferation, survival, and drug resistance, including PI3K/Akt/mTOR, NF‐κB, HER2/Akt, and Notch‐related signaling. However, these observations do not establish clinical efficacy or direct molecular target specificity. Pharmacokinetic studies have quantified systemic exposure to mollugin following oral administration of multicomponent Rubia cordifolia preparations, but the absolute oral bioavailability of purified mollugin remains undetermined. Furthermore, available toxicological investigations are insufficient to establish a comprehensive safety profile or a safe dietary exposure range. Important evidence gaps include repeated‐dose toxicity, genotoxicity, reproductive and developmental toxicity, metabolic disposition, and potential interactions. No controlled human evidence currently supports the clinical efficacy or safety of mollugin. Consequently, its application as a functional‐food or nutraceutical ingredient remains hypothetical and requires rigorous evaluation of botanical quality, oral exposure, pharmacokinetics, and toxicological safety. Overall, mollugin represents a compound of preclinical pharmacological interest whose potential food–health applications require further experimental validation.

Zitieren

APA

İlhan, M., Gök, H. N., Süntar, İ., Setzer, W. N., Sharifi‐Rad, J., & Calina, D. (2026). Mollugin as a Plant‐Derived Bioactive: Preclinical Pharmacology, Structure–Activity Relationships, Pharmacokinetic Evidence and Safety Requirements for Food–Health Translation. Food Safety and Health. https://doi.org/10.1002/fsh3.70132

Vancouver

İlhan M, Gök HN, Süntar İ, Setzer WN, Sharifi‐Rad J, Calina D. Mollugin as a Plant‐Derived Bioactive: Preclinical Pharmacology, Structure–Activity Relationships, Pharmacokinetic Evidence and Safety Requirements for Food–Health Translation. Food Safety and Health. 2026. doi:10.1002/fsh3.70132

BibTeX
@article{lhan2026,
  author = {İlhan, Mert and Gök, Hasya Nazlı and Süntar, İpek and Setzer, William N. and Sharifi‐Rad, Javad and Calina, Daniela},
  title = {Mollugin as a Plant‐Derived Bioactive: Preclinical Pharmacology, Structure–Activity Relationships, Pharmacokinetic Evidence and Safety Requirements for Food–Health Translation},
  journal = {Food Safety and Health},
  year = {2026},
  doi = {10.1002/fsh3.70132}
}
Kostenlos starten →